Silver Book Fact

Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.

Chestnut C, Skag A, Christiansen C, et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis. J Bone Miner Res. 2004; 19(8): 1241-9. http://www.ncbi.nlm.nih.gov/pubmed/15231010

Reference

Title
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Publication
J Bone Miner Res
Publication Date
2004
Authors
Chestnut C, Skag A, Christiansen C, et al
Volume & Issue
Volume 19, Issue 8
Pages
1241-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
  • Tools to Prevent Secondary Osteoporosis Fractures are Not Being Used
     
  • A meta-analysis of clinical trials found that calcium supplements reduced the risk of vertebral fractures by around 23%.